CRL
Charles River Laboratories
Health Care
Life Sciences Tools & Services
Wilmington, Massachusetts
Balance Sheet 43 Accounts • 5 Years
| Account | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| end | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | 2020-12-26 |
| Assets - CashAndCashEquivalents | $194.6M | $276.8M | $233.9M | $241.2M | $228.4M |
| Assets - AccountsReceivable | $720.9M | $780.4M | $752.4M | $642.9M | $617.7M |
| Assets - Inventories | $278.5M | $380.3M | $255.8M | $199.1M | $185.7M |
| Assets - ContractAssetsCurrent | $211.5M | $228.0M | $204.0M | $160.6M | $135.4M |
| Assets - PrepaidExpensesAndOtherCurrentAssets | $105.8M | $83.4M | $107.6M | $97.3M | $0 |
| Assets - TotalCurrentAssets | $1.4B | $1.6B | $1.4B | $1.3B | $1.2B |
| Assets - Property,PlantAndEquipment | $1.6B | $1.6B | $1.5B | $1.3B | $1.1B |
| Assets - Goodwill | $2.8B | $3.1B | $2.8B | $2.7B | $1.8B |
| Assets - IntangibleAssets(net,ExcludingGoodwill) | $723.4M | $864.1M | $955.3M | $1.1B | $787.6M |
| Assets - OperatingLeaseAssets | $412.5M | $394.0M | $391.8M | $292.9M | $178.2M |
| Assets - FinanceLeaseAssets | $28.9M | $29.4M | $31.9M | $29.4M | $31.6M |
| Assets - EquityMethodInvestments | $218.3M | $243.8M | $311.6M | $201.4M | $197.1M |
| Assets - DeferredTaxAssets | $317.7M | $290.3M | $258.7M | $221.1M | $169.2M |
| Assets - OtherNoncurrentAssets | $278.2M | $309.4M | $148.3M | $151.5M | $352.6M |
| Assets - TotalNoncurrentAssets | $1.6B | $1.6B | $1.5B | $1.3B | $1.1B |
| Assets - TotalAssets | $7.5B | $8.2B | $7.6B | $7.0B | $5.5B |
| Liabilities - AccountsPayable | $140.3M | $168.9M | $205.9M | $198.1M | $122.5M |
| Liabilities - AccruedLiabilities | $232.0M | $227.8M | $219.8M | $228.8M | $149.8M |
| Liabilities - ContractLiabilitiesCurrent(deferredRevenue) | $248.3M | $241.8M | $264.3M | $219.7M | $207.9M |
| Liabilities - ShortTermDebtAndCurrentPortionOfLongTermDebt | $155.0K | $3.2M | $1.3M | $101.0K | $47.2M |
| Liabilities - OperatingLeaseLiabilitiesCurrent | $54.2M | $54.9M | $46.5M | $33.3M | $24.7M |
| Liabilities - FinanceLeaseLiabilitiesCurrent | $2.8M | $2.4M | $2.3M | $2.7M | $3.0M |
| Liabilities - OtherCurrentLiabilities | $194.0M | $203.2M | $204.6M | $140.4M | $102.5M |
| Liabilities - TotalCurrentLiabilities | $994.1M | $1.1B | $1.1B | $1.0B | $839.8M |
| Liabilities - OperatingLeaseLiabilitiesNoncurrent | $483.8M | $419.2M | $389.7M | $253.0M | $155.6M |
| Liabilities - FinanceLeaseLiabilitiesNoncurrent | $25.7M | $26.2M | $28.3M | $24.5M | $26.0M |
| Liabilities - DeferredTaxLiabilitiesNoncurrent | $107.0M | $191.3M | $215.6M | $239.7M | $217.0M |
| Liabilities - PensionAndPostretirementBenefitLiabilitiesNoncurrent | $64.1M | $57.0M | $51.0M | $74.7M | $72.9M |
| Liabilities - OtherNoncurrentLiabilities | $195.2M | $223.2M | $174.8M | $242.9M | $205.2M |
| Liabilities - TotalLiabilities | $4.0B | $4.5B | $4.6B | $4.4B | $3.3B |
| Equity - PreferredStock | $0 | $0 | $0 | $0 | $0 |
| Equity - CommonStock | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K |
| Equity - AdditionalPaidInCapital | $2.0B | $1.9B | $1.8B | $1.7B | $1.6B |
| Equity - RetainedEarnings(deficit) | $1.8B | $1.9B | $1.4B | $980.8M | $625.4M |
| Equity - TreasuryStock | $119.2M | $24.2M | $38.7M | $40.7M | $24.0M |
| Equity - AccumulatedOtherComprehensiveIncome(loss) | $-317.3M | $-196.4M | $-262.1M | $-164.7M | $-138.9M |
| Equity - NoncontrollingInterest(permanentEquity) | $5.4M | $5.4M | $4.8M | $4.2M | $3.6M |
| Equity - RedeemableNoncontrollingInterest | $41.1M | $56.7M | $42.4M | $53.0M | $25.5M |
| Equity - TotalStockholdersEquity | $3.5B | $3.6B | $3.0B | $2.5B | $2.1B |
| Equity - TotalLiabilitiesAndStockholdersEquity | $7.5B | $8.2B | $7.6B | $7.0B | $5.5B |
| Equity - TotalLiabilitiesandEquity | $7.5B | $8.1B | $7.6B | $7.0B | $5.5B |
| Validation - L+E Components Sum Difference | $0 | $0 | $0 | $0 | $0 |